Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic
episodes responded to aripiprazole treatment. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1209. 2009 Authors' conclusions Aripiprazole (Abilify®) is recommended as an option for use within NHS Wales for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
Aripiprazole (Abilify®) may be suitable for shared care when used for long term treatment (i.e. prevention of manic episode) after hospital initiation. Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic Agents; Bipolar Disorder; Humans; Piperazines; Quinolones Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000411 Date abstract record published 08/08/2012 |